News

Australian authorities are alerting Multiple Sclerosis patients to the risk of unproven stem cell treatments that are being performed both in the country and overseas, after the recent death of a woman in Russia undergoing a controversial treatment for the disease. The continued marketing campaigns to…

Synthetic Biologics, Inc., a biotechnology company developing novel drug candidates targeting specific pathogens that cause serious infections and diseases, announced that its latest data on Trimesta™, regarding cognitive and disability measures in women suffering from multiple sclerosis (MS), will be presented at the 2014 Joint Americas and European Committees…

Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute have made encouraging advances in the development of a viable cell replacement therapy for multiple sclerosis using a patient’s own cells, known as induced pluripotent stem cells (iPSCs). Since multiple sclerosis is a chronic demyelinating disease of unknown…

In spite of an eight week delay, New Zealand-based Innate Immunotherapeutics is still planning to enroll patients for its phase 2b clinical trial that will study the experimental drug MIS416 for secondary progressive MS. The clinical research organization (CRO) involved in the management of the trial informed the company about the…

The European Commission granted marketing authorization for the use of Plegridy, a drug developed by Biogen Idec as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). The approval comes at a time when…

Complementary and alternative medicine (CAM) are no substitutes for the regular treatment of multiple sclerosis (MS), however, they are becoming more common among patients as a way of alleviating the symptoms of the disease. Massage therapy is an example of that. 36-year-old Jessica Rich is a patient who embraced…

The U.S. Food and Drug Administration (FDA) recently notified Concert Pharmaceuticals that the company had fulfilled all necessary preclinical toxicological tests for the oral therapy CTP-354 for the treatment of multiple sclerosis, spinal cord injury, and spasticity. The authorization to administer repeated doses of the compound, in excess of 6 mg per day,…

For the approximately 15-20% of multiple sclerosis patients with acute optic neuritis (AON), lack of vitamin D may be partly responsible. A new study published in Neurology identified a link between vitamin D levels and AON severity. Individuals with higher vitamin D levels may experience less severe…

A Ph.D. student at the University of Southern California (USC) Viterbi Ming Hsieh Department of Electrical Engineering, Kun Yue, is developing a model of selected brain circuits to study multiple sclerosis (MS) in an effort to develop a nanotechnology based treatment for the disease. Yue believes that new technology can lead…

The next Bike Multiple Sclerosis Cactus and Crude event, a bike run hosted by the National MS Society to raise awareness on this disease, will take place this weekend at the starting line in Midland, TX gathering 200 to 250 cyclists that will ride a total of…

The UK’s National Institute for Health and Care Excellence (NICE) gave a positive final appraisal determination to the use of the Biogen Idec‘s drug Tecfidera (dimethyl fumarate) in adults for the treatment of relapsing-remitting multiple sclerosis (RRMS), having turned back on their preliminary negative recommendation. The oral…

Alkermes plc is looking to add one more treatment to the repertoire for multiple sclerosis drugs by initiating a Phase 1 clinical trial study of ALKS 8700. This novel molecule, developed by Alkermes, will be evaluated for safety, tolerability, and pharmacokinetics. “We expect the results of this study to…

Eight new drugs that are able to stimulate the nervous system were discovered by a research team at UC San Francisco recently. The team utilized a novel screening platform and examined the cellular effects of 1,000 chemical compounds. The scientists believe the discovery may impact the treatment of the tissue…

Startup biotech company ImStem Biotechnology is looking to raise additional funding for their upcoming clinical trials after publishing promising research on a unique stem-cell treatment used on mice with multiple sclerosis.  The company has already received previous funding…

The Scottish Medicines Consortium (SMC)  announced the approval of the drug Lemtrada, produced by Genzyme, for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) and active disease defined by clinical or imaging features, within the national health system (NHS) in Scotland. Lemtrada…

The American Public Broadcasting Service (PBS) recently aired a documentary about a University of Central Oklahoma (UCO) music professor, who suffers from multiple sclerosis (MS), on OETA. “Healed: Music, Medicine and Life with MS,” tells the story of Jim Klages‘s struggle against the disease. Klages was an accomplished musician and…

According to a study published in JAMA Neurology, multiple sclerosis patients are greatly benefited by Biogen Idec’s Tysabri (natalizumab) and tend to relapse if they discontinue treatment. Natalizumab had a protective effect on patients who were continuously treated with Tysabri beyond a 24-dose timepoint within the study,…

The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis has recently announced the first MENACTRIMS Congress for professionals to be held in Dubai on the 17th and 18th of October. While Multiple Sclerosis (MS) is often associated with North America and Northern Europe, the disease…

Bike MS, a two-day ride between Westminster and Fort Collins, in Colorado, raised $3.8 million to support the multiple sclerosis (MS) research, thanks to the help of over 3,000 riders, volunteers, and advocates. Bikers started the journey last Saturday and rode back to Westminster Sunday morning. The money raised, from…

The University of California, San Francisco (UCSF) initiated a clinical trial to evaluate the antihistamine clemastine fumarate, manufactured by Novartis as Tavist, for its efficacy in treating multiple sclerosis patients. The laboratory of Dr. Jonah Chan, a professor of neurology at UCSF, used a high-throughput method to identify Tavist…

The main costs of care for multiple sclerosis (MS) patients continue to be driven predominantly by common MS “sequelae” — a condition that is the consequence of a previous disease or injury — according to a recent study from the BMC Health Services Research. However, in spite of cost drivers remaining steady,…

The Republic of Ireland is legalizing the medical prescription of cannabis for people with Multiple Sclerosis, under a new revision to current Irish laws. The Irish Mirror reports that Pat O’Mahony, CEO of Ireland’s Health Products Regulatory Authority (HPRA) confirmed July 7 that the Department of Health is…

An Everyday Health blog by New Jersey-based husband and wife team Brad and Robynn Mann notes that more time spent outdoors during the warmer months means more potential encounters with insects that can be disease vectors, notably mosquitos and ticks. Mr. Mann, who is diagnosed with Multiple Sclerosis (MS),…

Stem therapy to treat multiple sclerosis may benefit greatly from a new study published in Proceedings of the National Academy of Sciences by the laboratory of Fraser Sim, Ph.D., assistant professor of Pharmacology and Toxicology at University of Buffalo’s School of Medicine and Biomedical Sciences. Dr.

Tracking patients’ progress is a critical part of MS management, a process that can benefit from greater objective analysis. Researchers at the Cleveland Clinic have determined that tablet computers, which feature built-in technologies like accelerometers, gyroscopes, and touchscreens, when combined with appropriate software, can provide pretty good MS assessment capabilities.

Lemtrada, a drug produced by Genzyme for the treatment of adult patients suffering from relapsing remitting multiple sclerosis (RRMS) with active disease, was approved by Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT). “We are pleased by the continued global support for Lemtrada,” said Genzyme…

Acorda Therapeutics recently announced receiving a notice letter from pharmaceutical company Actavis Plc indicating their plans to commercialize a generic version of Ampyra, Acorda’s multiple sclerosis treatment drug. Acorda claims that Actavis submitted a marketing approval application with the U.S. Food and Drug Administration (FDA) asking permission to develop and commercialize a new drug,…

Fatigue, a common symptom of multiple sclerosis, could be a result of regional damage in the brain. A study published in Radiology by a group in Italy led by Massimo Filippi, MD, from Vita-Salute San Raffaele University showed that local, rather than global, atrophy is associated with fatigue.

The Conrad N. Hilton Foundation is accepting submissions for the first edition of the Marilyn Hilton Award for Innovation in Multiple Sclerosis Research, which will support novel and potentially paradigm-shifting research on Progressive Multiple Sclerosis (MS). The award will grant up to $6 million in funding to several projects over a four-year…

Researchers at the Kessler Foundation bolstered the knowledge of cognitive decline in multiple sclerosis patients with an article published in Multiple Sclerosis and Related Disorders. This longitudinal study is one of the longest among studies of cognition in multiple sclerosis. “While cognitive impairment is known to affect…